Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Blood (2023) 141 (7): 800–805.

https://doi.org/10.1182/blood.2022017874

Published: 2023

Includes: Supplemental data

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma

Michael D Ashby, Natasha S Anstee, Tongted Das, Ing S Tiong, Sun Loo, Andrew Spencer, Andrew H. Wei

Blood (2022) 140 (Supplement 1): 2876–2878.

https://doi.org/10.1182/blood-2022-165544

Published: 2022

Journal Articles

Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy

Anna Maierhofer, Lucy C Fox, Stephan Hutter, Constance Baer, Ella Thompson, Tamia Nguyen, Nicole Den Elzen, Robin J Filshie, Ing S Tiong, Niroshan Nadarajah, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Piers Blombery

Blood (2022) 140 (Supplement 1): 8676–8677.

https://doi.org/10.1182/blood-2022-163064

Published: 2022

Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Blood (2022) 140 (Supplement 1): 3341–3343.

https://doi.org/10.1182/blood-2022-167837

Published: 2022

Journal Articles

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

Ing S Tiong, Adam Ivey, Katherine Fielding, Chun Yew Fong, Andrew H Wei

Blood (2022) 140 (Supplement 1): 6258–6259.

https://doi.org/10.1182/blood-2022-163093

Published: 2022

Journal Articles

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Chong Chyn Chua, Sun Loo, John Reynolds, Ing S Tiong, Chun Yew Fong, Stephen B Ting, Shaun Fleming, Andrew W Roberts, Andrew H Wei

Blood (2022) 140 (Supplement 1): 1708–1710.

https://doi.org/10.1182/blood-2022-165021

Published: 2022

Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei

Blood (2022) 140 (Supplement 1): 1453–1455.

https://doi.org/10.1182/blood-2022-163041

Published: 2022

Journal Articles

Favorable Outcomes of DDX41 -Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

Ing S Tiong, William S Stevenson, Meaghan Wall, Yan Zhuang Yap, John F. Seymour, Melita Kenealy, Piers Blombery

Blood (2022) 140 (Supplement 1): 4090–4091.

https://doi.org/10.1182/blood-2022-162880

Published: 2022

Journal Articles

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Imogen R Caldwell, Michael Ingbritsen, Yan Zhuang Yap, Mark R Dowling, Ing S Tiong, David A Westerman, Piers Blombery

Blood (2022) 140 (Supplement 1): 10731–10732.

https://doi.org/10.1182/blood-2022-162228

Published: 2022

Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Blood (2022) 140 (Supplement 1): 2033–2035.

https://doi.org/10.1182/blood-2022-159467

Published: 2022

Journal Articles

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

Georgina L Ryland, Ashish Bajel, Michael Dickinson, Paul G Ekert, Oliver Hofmann, Maarten IJzerman, Ashley P Ng, Alicia Oshlack, Breon Schmidt, Ing S Tiong, Martin Vu, David Alan Westerman, Sean Grimmond, Piers Blombery

Blood (2021) 138 (Supplement 1): 274.

https://doi.org/10.1182/blood-2021-146396

Published: 2021

Journal Articles

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Sun Loo, Richard Dillon, Natasha S Anstee, Ing S Tiong, Adam Ivey, Nicola Potter, Jad Othman, Manohursingh Runglall, Jelena Jovanovic, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2364.

https://doi.org/10.1182/blood-2021-149301

Published: 2021

Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 1261.

https://doi.org/10.1182/blood-2021-152583

Published: 2021

Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2648.

https://doi.org/10.1182/blood-2019-123899

Published: 2019

Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): 333.

https://doi.org/10.1182/blood-2018-99-114243

Published: 2018

Journal Articles

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Andrew H. Wei, Ing S. Tiong

Blood (2017) 130 (23): 2469–2474.

https://doi.org/10.1182/blood-2017-08-784066

Published: 2017

NARROW

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma

Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Favorable Outcomes of DDX41 -Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only